Evidence map›Paper›PMID 37251937›Full record

ArticleFrontiers in oncology2023

Delta-radiomics based on CT predicts pathologic complete response in ESCC treated with neoadjuvant immunochemotherapy and surgery.

Kaiyuan Li, Yuetong Li, Zhulin Wang, Chunyao Huang, Shaowu Sun, Xu Liu, Wenbo Fan, Guoqing Zhang, Xiangnan Li

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 2 pooled it
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Kaiyuan LiDepartment of Thoracic Surgery, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Yuetong LiClinical Medical College, Henan University, Henan, Kaifeng, China.
Zhulin WangDepartment of Thoracic Surgery, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Chunyao HuangDepartment of Thoracic Surgery, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Shaowu SunDepartment of Thoracic Surgery, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Xu LiuDepartment of Thoracic Surgery, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Wenbo FanDepartment of Thoracic Surgery, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Guoqing ZhangDepartment of Thoracic Surgery, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Xiangnan LiDepartment of Thoracic Surgery, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
First Affiliated Hospital of Zhengzhou University · CNHenan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and purpose: Unnecessary surgery can be avoided, and more appropriate treatment plans can be developed for patients if the efficacy of neoadjuvant immunochemotherapy for esophageal cancer (EC) can be predicted before surgery. The purpose of this study was to evaluate the ability of machine learning models based on delta features of immunochemotherapy CT images to predict the efficacy of neoadjuvant immunochemotherapy in patients with esophageal squamous cell carcinoma (ESCC) compared with machine learning models based solely on postimmunochemotherapy CT images. Materials and methods: A total of 95 patients were enrolled in our study and randomly divided into a training group (n = 66) and test group (n = 29). We extracted preimmunochemotherapy radiomics features from preimmunochemotherapy enhanced CT images in the preimmunochemotherapy group (pregroup) and postimmunochemotherapy radiomics features from postimmunochemotherapy enhanced CT images in the postimmunochemotherapy group (postgroup). We then subtracted the preimmunochemotherapy features from the postimmunochemotherapy features and obtained a series of new radiomics features that were included in the delta group. The reduction and screening of radiomics features were carried out by using the Mann-Whitney U test and LASSO regression. Five pairwise machine learning models were established, the performance of which was evaluated by receiver operating characteristic (ROC) curve and decision curve analyses. Results: The radiomics signature of the postgroup was composed of 6 radiomics features; that of the delta-group was composed of 8 radiomics features. The area under the ROC curve (AUC) of the machine learning model with the best efficacy was 0.824 (0.706-0.917) in the postgroup and 0.848 (0.765-0.917) in the delta group. The decision curve showed that our machine learning models had good predictive performance. The delta group performed better than the postgroup for each corresponding machine learning model. Conclusion: We established machine learning models that have good predictive efficacy and can provide certain reference values for clinical treatment decision-making. Our machine learning models based on delta imaging features performed better than those based on single time-stage postimmunochemotherapy imaging features.

Indexed as

delta radiomicsesophageal cancermachine learningneoadjuvant immunochemotherapypathological complete response

Identifiers

PMID37251937
PMCPMC10213404
OpenAlexW4376279779

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.